Cat. No. 1332
Chemical Name: (2R)-2-[[9-(1-Methylethyl)-6-[(phen
Biological ActivityPotent, selective inhibitor of cyclin-dependent kinases (cdk). Inhibits cdc2/cyclin B (IC50 = 650 nM), cdk2/cyclin A (IC50 = 700 nM), cdk2/cyclin E (IC50 = 700 nM), cdk5 / p35 (IC50 = 160 nM) and is selective over cdk4/cyclin D1 and cdk6/cyclin D3 (IC50 > 100 μM). Also selective over a wide range of related kinases including ERK1 and ERK2. Arrests L1210 cells in G1 phase. Inhibits phosphorylation of vimentin in vivo. Antimitotic.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
De Azevedo et al (1997) Inhibition of cyclin-dependent kinases by purine analogues. Eur.J.Biochem. 243 518. PMID: 9030780.
Meijer et al (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur.J.Biochem. 243 527. PMID: 9030781.
Meijer (1996) Chemical inhibitors of cyclin-dependent kinases. Trends Cell.Biol. 6 393. PMID: 15157522.
If you know of a relevant reference for Roscovitine please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Roscovitine from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Roscovitine, supplier, Potent, selective, inhibitors, inhibits, cyclin, dependent, kinases, cdks, cdc2, cyclin, B, cdk2, cyclin, A, cdk2, cyclin, E, cdk5, p35, antimitotic, Tocris Bioscience, Cyclin-Dependent Protein Kinase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Serine/threonine protein kinase 16 (STK16) inhibitor; also inhibits P13Kδ, P13Kγ and mTOR kinases.AZ PFKFB3 26
Potent and selective PFKFB3 inhibitorNCL 00017509
Potent and reversible NIMA related kinase 2 (Nek2) inhibitorXMD 8-87
Potent Ack1/TNK2 inhibitorSKI 178
Non-lipid sphingosine kinase 1 (SphK1) inhibitorML 315 hydrochloride
Inhibitor of Clk and DYRK kinasesEverolimus
mTOR inhibitor;immunosuppressantPKI (5-24)
High affinity PKA inhibitorTDZD 8
Selective non-ATP competitive inhibitor of GSK 3βBI 605906
Selective IKKβ inhibitorGSK 319347A
Potent and selective IKKε inhibitorFRAX 597
Potent group I PAK inhibitorMRT 68921 dihydrochloride
Potent ULK inhibitor; inhibits autophagyAM 2394
Potent glucokinase activator; orally bioavailableeCF 309
Potent mTOR inhibitorPF 3758309 dihydrochloride
Potent PAK4 inhibitor; orally availableAZ Dyrk1B 33
Potent and selective Dyrk1B kinase inhibitorPF 06409577
Potent and selective allosteric activator of AMPKPerifosine
PKB/Akt inhibitor; also modulates Kv2.1 currentRAF 265
Raf kinase and VEGFR-2 inhibitorCZC 25146
Potent LRRK2 inhibitorRo 3280
Potent and selective PLK1 inhibitorRMM 46
MSK/RSK family kinase inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.